porcin
epidem
diarrhea
viru
pedv
predomin
caus
sever
enteropathogen
diarrhea
swine
lack
effect
therapeut
treatment
underlin
import
research
new
antivir
studi
identifi
activ
inhibit
pedv
replic
inhibitori
concentr
ic
gml
cytotox
concentr
cc
gml
deriv
therapeut
index
sever
structur
analogu
quercetin
apigenin
luteolin
catechin
also
show
moder
antipedv
activ
antivir
drug
natur
compound
reveal
ribavirin
coumarin
tannic
acid
rel
weaker
efficaci
compar
directli
interact
inactiv
pedv
particl
affect
initi
stage
pedv
infect
interf
pedv
replic
also
effect
two
virus
tgev
prcv
lower
compar
pedv
could
consid
lead
compound
develop
antipedv
drug
may
use
earli
stage
pedv
replic
structureact
data
may
use
guidelin
design
relat
antivir
agent
porcin
epidem
diarrhea
viru
pedv
famili
coronavirida
caus
porcin
epidem
diarrhea
enter
diseas
character
acut
wateri
diarrhea
dehydr
vomit
high
mortal
nurseri
piglet
debouck
pensaert
infect
viru
becom
seriou
issu
swine
industri
outbreak
lead
seriou
econom
loss
mani
countri
hofmann
wyler
unfortun
effect
commerci
vaccin
specif
treatment
avail
measur
control
diseas
direct
prevent
entranc
viru
farm
medicin
plant
increasingli
pursu
suitabl
altern
sourc
discoveri
antivir
agent
briskin
cowan
jassim
naji
vlietinck
vanden
bergh
william
recent
studi
demonstr
houttuynia
cordata
thunb
saururacea
effect
treat
anaphylaxi
cancer
kwon
et
al
li
et
al
lu
et
al
also
shown
essenti
oil
prepar
correspond
author
tel
fax
email
address
dhkwon
kribbrekr
dh
kwon
fresh
plant
h
cordata
possess
direct
inhibitori
activ
herp
simplex
viru
type
influenza
viru
human
immunodefici
viru
type
without
show
cytotox
lu
et
al
particular
quercetin
flavonoid
present
h
cordata
report
inhibitori
effect
sever
virus
mucsi
pragai
although
varieti
pharmacolog
activ
associ
chemic
h
cordata
demonstr
antivir
activ
pedv
report
studi
examin
posit
effect
hydroxyl
group
within
basic
flavonoid
structur
type
posit
attach
sugar
pedv
replic
furthermor
elucid
action
pedv
multipl
detail
investig
effect
infect
cycl
pedv
timeofaddit
studi
rtpcr
analysi
effect
infect
pedv
particl
tamiflu
f
hofmannla
roch
ltd
switzerland
relenza
laboratoir
glaxosmithklin
franc
lamivudin
glaxosmithklin
australia
pti
ltd
australia
purchas
pharmaci
korea
prescrib
medic
doctor
acriflavin
acycloguanosin
azidovudin
caffein
cumarin
glycyrrhizin
riboflavin
tannic
acid
quercetin
apigenin
luteolin
catechin
quercetrin
genistin
hesperidin
rutin
sulforhodamin
b
srb
purchas
sigmaaldrich
st
loui
mo
usa
chemic
reagent
grade
vero
african
green
monkey
kidney
cell
line
atcc
st
pig
testi
cell
line
atcc
tgev
transmiss
gastroenter
viru
atcc
prcv
porcin
respiratori
coronaviru
atcc
kindli
provid
atcc
american
type
cultur
collect
manassa
va
usa
pedv
cv
porcin
epidem
diarrhea
viru
obtain
nation
veterinari
research
quarantin
servic
korea
vero
st
cell
line
maintain
minim
essenti
medium
mem
supplement
fetal
bovin
serum
fb
antibioticantimycot
antibioticantimycot
trypsinedta
fb
mem
suppli
gibco
brl
grand
island
ny
usa
tissu
cultur
plate
purchas
falcon
bd
bioscienc
nj
usa
aerial
part
h
cordata
collect
gyeongsangnamdo
agricultur
research
extens
servic
korea
august
dri
ground
materi
kg
extract
three
time
meoh
l
room
temperatur
day
extract
perform
srbbase
cytotox
antivir
activ
assay
tabl
meoh
extract
g
ic
gml
cc
gml
separ
two
fraction
use
etoac
nonaqu
phase
concentr
etoac
fraction
g
ic
gml
cc
gml
load
silica
gel
merck
mesh
g
column
elut
stepgradi
chcl
meoh
l
afford
eight
fraction
activ
fraction
chcl
meoh
fraction
g
ic
cc
separ
use
sephadex
amersham
pharmacia
biotech
ab
sweden
mesh
g
elut
success
methanolwat
vv
l
fraction
obtain
purif
activ
fraction
combin
fraction
g
ic
cc
gml
subject
analyt
hplc
ymcpack
odsma
id
mm
mm
eluent
aq
acetonitril
flow
rate
mlmin
uv
nm
gave
pure
compound
mg
ic
gml
cc
gml
base
electron
spray
ionizationmass
spectrometri
h
nmr
c
nmr
spectral
data
purifi
compound
verifi
quercetin
awaad
et
al
one
day
infect
vero
cell
seed
onto
cultur
plate
concentr
cell
per
well
next
day
medium
remov
wash
phosphat
buffer
salin
pb
infect
viru
stock
determin
srb
method
use
cytopath
effect
cpe
reduct
determin
infect
viru
srb
id
infect
dose
follow
ml
dilut
viru
suspens
pedv
contain
ccid
cell
cultur
infect
dose
viru
stock
produc
appropri
cytopath
effect
within
day
infect
ml
medium
supplement
typsinedta
contain
appropri
concentr
compound
ad
antivir
activ
test
materi
determin
dilut
concentr
rang
gml
three
well
use
viru
control
virusinfect
nondrugtr
cell
three
well
use
cell
control
noninfect
nondrugtr
cell
cultur
plate
incub
c
co
day
wash
time
pb
l
cold
c
aceton
ad
well
left
min
c
aceton
remov
plate
left
dri
oven
min
l
wv
srb
acet
acid
solut
ad
well
left
room
temperatur
min
unbound
srb
remov
plate
wash
time
acet
acid
oven
dri
left
dri
oven
day
bound
srb
solubil
l
mm
unbuff
trisbas
solut
plate
left
tabl
min
absorb
read
nm
use
versamax
micropl
reader
molecular
devic
palo
alto
ca
usa
refer
absorb
nm
calcul
ic
valu
result
transform
percentag
control
ic
valu
graphic
obtain
doserespons
curv
percent
protect
achiev
test
compound
pedvinfect
cell
calcul
follow
formula
od
pedv
optic
densiti
measur
given
concentr
test
compound
pedvinfect
cell
od
c
pedv
optic
densiti
measur
control
untreat
pedvinfect
cell
od
c
mock
optic
densiti
measur
control
untreat
mockinfect
cell
concentr
achiev
protect
accord
formula
defin
inhibitori
concentr
ic
therapeut
index
defin
cc
ic
test
effect
infect
pedv
particl
pedv
preincub
gml
h
c
vero
cell
infect
pretreat
untreat
pedv
h
c
unbound
viru
remov
wash
time
pb
ant
cell
incub
infect
medium
supplement
without
gml
c
antivir
activ
determin
srb
assay
day
timeofaddit
effect
examin
accord
previous
describ
procedur
minor
modif
chiang
et
al
b
vero
cell
seed
onto
cultur
plate
densiti
cell
per
well
incub
day
wash
pb
gml
ribavirin
ad
onto
cell
either
h
h
h
period
pedv
infect
day
antivir
activ
carri
describ
ribavirin
use
posit
control
cytotox
evalu
modifi
srb
assay
previous
describ
lin
et
al
vero
cell
seed
onto
cultur
plate
concentr
cell
per
well
next
day
medium
remov
plate
replac
media
contain
serial
dilut
compound
cell
incub
h
cultur
medium
remov
wash
pb
next
step
conduct
antivir
activ
assay
obov
describ
calcul
cc
valu
result
transform
percentag
control
cc
valu
graphic
obtain
doserespons
curv
vero
cell
seed
onto
cultur
plate
concentr
cell
per
well
next
day
medium
remov
cell
wash
pb
ml
dilut
viru
suspens
ml
medium
supplement
typsinedta
contain
ribavirin
gml
ad
incub
c
co
h
next
step
perform
total
rna
extract
cultur
cell
acid
guanidinium
thiocyanatephenolchloroform
extract
method
chomczynski
mackey
total
rna
dissolv
diethylpyrocarbon
sigma
treat
water
amount
rna
determin
measur
spectrometr
absorb
nm
check
puriti
ribosom
rna
rna
gml
load
rna
gel
buffer
ribosom
rna
band
compar
firststrand
cdna
synthes
total
rna
rnasefre
condit
reaction
perform
g
total
rna
use
firststrand
rtpcr
kit
stratagen
la
jolla
ca
usa
accord
manufactur
instruct
pcr
perform
geneamp
pcr
system
perkinelmercetu
norwalk
ct
usa
use
firststrand
cdna
taq
polymeras
takara
shuzo
kyoto
japan
follow
primer
membran
gene
pedv
pcramplifi
product
separ
agaros
gel
contain
gml
ethidium
bromid
visual
uv
light
current
antivir
drug
natur
compound
flavonoid
studi
inhibitori
effect
replic
pedv
cytotox
vero
cell
among
ribavirin
tannic
acid
coumarin
exhibit
activ
ic
gml
unit
respect
cc
gml
unit
therapeut
indic
respect
quercetin
apigenin
luteolin
catechin
show
antipedv
activ
ic
less
gml
cc
gml
respect
furthermor
show
highest
ti
pedv
test
ic
gml
cc
gml
tabl
basi
result
relationship
flavonoid
structur
antivir
activ
pedv
evalu
among
flavonoid
test
flavon
ie
apigenin
luteolin
flavonol
ie
flavan
ie
catechin
odihydroxi
function
group
show
signific
antipedv
activ
addit
flavonol
possess
one
rhamnosid
posit
dihydroxyl
group
also
found
antivir
activ
higher
flavonoid
antipedv
activ
quercetin
five
hydroxyl
group
decreas
ic
valu
less
indic
sugar
group
are
import
featur
antipedv
activ
flavonoid
observ
effect
infect
pedv
particl
exam
perform
antivir
activ
preincub
ribavirin
result
respect
contrast
continu
presenc
infect
led
signific
increas
antivir
activ
similar
result
obtain
control
infect
treat
ribavirin
fig
antivir
activ
shown
lower
indic
interact
particl
pedv
preexposur
viru
alter
infect
pedv
particl
ad
differ
period
pedv
infect
result
show
suppress
pedv
infect
ad
viru
inocul
h
result
present
mean
valu
obtain
three
independ
experi
carri
triplic
sd
concentr
requir
inhibit
virusinduc
cpe
gml
b
concentr
requir
reduc
cell
growth
gml
c
therapeut
index
fig
effect
infect
pedv
particl
pedv
particl
incub
gml
h
c
afterward
vero
cell
incub
untreat
viru
h
c
unbound
viru
remov
extens
wash
infect
continu
cultiv
cell
infect
medium
without
gml
c
antivir
activ
determin
titrat
use
srb
assay
day
postinfect
preinc
preincub
express
incub
without
gml
wash
inc
incub
express
incub
gml
wash
also
earli
viru
inocul
h
ribavirin
also
show
weak
effect
pedv
infect
inhibitori
either
amount
level
higher
fig
ribavirin
lower
howev
inhibitori
rate
two
compound
declin
less
ad
either
prior
h
post
h
infect
observ
indic
affect
initi
stage
pedv
infect
evid
inhibitori
effect
infect
pedv
viral
replic
vero
cell
provid
pcr
analysi
rna
extract
perform
h
pedv
infect
gml
decreas
intens
product
fig
rtpcr
analysi
replic
pedv
vero
cell
h
infect
pedv
presenc
gml
ribavirin
gml
vehicl
alon
control
dmso
detect
rtpcr
band
pedv
h
infect
ribavirin
gml
decreas
intens
product
band
pedv
h
infect
fig
two
virus
select
experi
includ
tgev
prcv
st
cell
antivir
activ
cytotox
ribavirin
examin
srb
assay
two
compound
exhibit
cytotox
highest
concentr
test
tabl
ic
valu
ribavirin
tgev
gml
respect
prcv
gml
respect
furthermor
ti
valu
great
differ
two
virus
sever
veterinari
coronaviru
vaccin
current
avail
efficaci
variabl
vaccin
prevent
infecti
bronchiti
viru
ibv
infect
chicken
effect
ladman
et
al
canin
porcin
vaccin
partial
effect
pratelli
et
al
ribavirin
use
treat
variou
dna
rna
viru
infect
although
virusacquir
resist
isol
variou
viru
popul
observ
patient
jason
craig
antivir
studi
shown
essenti
oil
prepar
fresh
plant
h
cordata
inhibitori
effect
herp
simplex
viru
type
influenza
viru
human
immunodefici
viru
type
without
show
cytotox
lu
et
al
quercetin
report
inhibitori
effect
sever
virus
mucsi
pragai
studi
indic
h
cordata
possess
compound
exhibit
antivir
effect
studi
effect
antivir
compound
pedv
mark
inhibitori
effect
growth
tgev
prcvinfect
cell
antivir
activ
compound
appear
strongli
influenc
strain
coronavirus
test
ribavirin
broadspectrum
nucleosid
analogu
exhibit
result
present
mean
valu
obtain
three
independ
experi
carri
triplic
sd
concentr
requir
inhibit
virusinduc
cpe
gml
b
concentr
requir
reduc
cell
growth
gml
c
therapeut
index
expect
antivir
activ
broadspectrum
antivir
drug
previous
shown
inhibitori
dna
rna
virus
cell
cultur
sidwel
et
al
trial
ribavirin
studi
show
drug
favor
effect
antivir
activ
vero
cell
infect
pedv
tgev
prcv
ribavirin
weaker
influenc
surviv
vero
cell
infect
tgev
prcv
howev
abl
ascertain
ribivirin
possess
antivir
activ
elucid
action
pedv
multipl
detail
investig
effect
singl
step
infect
cycl
pedv
result
conclud
interact
particl
pedv
preexposur
viru
alter
infect
pedv
particl
fig
base
result
timecours
studi
preincub
vero
cell
protect
cell
pedv
infect
fig
furthermor
inhibit
pedv
infect
ad
earli
stage
viru
inocul
h
h
later
fig
suggest
mode
action
deriven
inhibit
absorpt
viru
result
inhibit
earli
stage
viral
replic
infect
fig
among
flavonoid
test
possess
signific
activ
pedv
previou
report
rutin
express
antivir
activ
wherea
quercitrin
quercetin
possess
similar
activ
quercetin
human
herpesvirus
adenovirus
chiang
et
al
b
found
antivir
activ
among
flavonoid
glycosid
contain
quercetin
moieti
might
correl
speci
sugar
group
posit
result
suggest
antivir
activ
flavonoid
pedv
correl
speci
sugar
group
posit
conclus
present
studi
describ
possess
strong
antipedv
activ
among
flavonoid
interest
investig
antivir
activ
prevent
variou
pedvmedi
injuri
vivo
patholog
situat
studi
requir
explor
detail
antivir
mechan
